|
|
||||||||
1 From the Department of Zoology, Göteborg University, Sweden; the 2 Wallenberg Retina Center, Lund University, Sweden; and the 3 Department of Psychonomics, Utrecht University, The Netherlands.
| Abstract |
|---|
|
|
|---|
METHODS. Postnatal day (PN)2 or PN7 control and rd mouse retinas were grown with attached retinal pigment epithelium (RPE). The explants were kept in culture up to PN28. During this culture period CNTF, BDNF, CNTF+BDNF, or vehicle were continuously administered to the culture medium. The nontrophic factors cyclosporin A and N-CBZ-aspartic acid-glutamic acid-valine-aspartic acid-fluoromethyl ketone (z-DEVD-fmk) were also used. The number of photoreceptor nuclei remaining in the outer nuclear layer (ONL) was analyzed in hematoxylin and eosinstained sections. Rod- and cone-specific antibodies were used to determine identity and state of differentiation of the photoreceptors.
RESULTS. Compared with vehicle treatment, BDNF or CNTF resulted in 1.4- or 2-fold more surviving cell rows in the ONL, respectively. However, when CNTF and BDNF were applied together, surviving ONL cell counts in the rd explants were approximately 3 times those in vehicle-treated explants. In the presence of CNTF or CNTF+BDNF, opsin and arrestin expression in rods was decreased compared with rods without attached RPE. Cyclosporin A and z-DEVD-fmk did not show rescue of rd photoreceptor cells.
CONCLUSIONS. CNTF or BDNF treatment of rd retinal explants delays photoreceptor cell loss to some extent. However, when these agents are combined, photoreceptor rescue is much more effective. The quenching of opsin and arrestin expression caused by treatment suggests that simultaneous with rod rescue, rod differentiation is depressed. Regarding retinal degeneration, the results from the selective inhibitors of apoptosis rank the CNTF+BDNF combination treatment as the most consistent and effective experimental pharmacologic intervention currently available.
| Introduction |
|---|
|
|
|---|
Various neurotrophic factors have been tested for their ability to slow retinal cell loss.13 Some have been found to be effective when injected into the vitreous and subretinal space,14 when applied to dissociated cultures,15 or as a supplement to transplants.16 We have shown that a combination of basic fibroblast growth factor (FGF2) and nerve growth factor (NGF), but not these agents on their own, retards rd photoreceptor cell loss in organ culture.12 A key emerging theme is the requirement for combinations of specific agents when designing an effective pharmacologic intervention for neuroprotection. Regarding protection of photoreceptor cells against hereditary degeneration, recent data have indicated that another pair of neurotrophic factors, ciliary neurotrophic factor (CNTF) and brain-derived neurotrophic factor (BDNF), are effective in delaying cell loss in rd retinal tissue in culture.17 The combination of CNTF and BDNF has demonstrated powerful neuroprotection of developing retinal ganglion cells and in motor neuron disease as well.18 19
A purpose of our study, from which we report the results, was to investigate the combined effect of CNTF and BDNF on photoreceptor survival in detail. We wanted to gather sufficient information regarding dosage, reliability, duration of effect, and relative effectiveness of the combination treatment compared with application of the individual factors. For this, our neonatal retinal explant procedure has been used. While examining the immunolabeled sections, we noted a drug-induced decrease in opsin immunoreactivity when in contact with the RPE. This phenomenon was investigated further because this observation appealed to reports that CNTF blocks photoreceptor differentiation in vitro.20 The results presented herein enable a better understanding and interpretation of effects displayed by the neurotrophic factors and the role of the RPE.
| Materials and Methods |
|---|
|
|
|---|
Retinas were incubated in 1.2 ml of R16 medium (Gibco, Gaithersburg, MD) with 10% or 2% fetal bovine serum (FBS; Gibco). For vehicle treatment either no further agents or dimethyl sulfoxide (DMSO) was added to the culture medium. The latter was used as a control for agents dissolved in DMSO-containing solution. For the neurotrophic factor treatment groups, the serum medium was supplemented with 50 ng/ml or 10 ng/ml of either recombinant rat CNTF or recombinant human BDNF (Saveen; ReproTech, Rocky Hill, NJ) or both. For the other treatment groups the medium was supplemented with either cyclosporin A (CsA; 25 µg/ml) or the N-carbobenzoxy amino acid sequence N-CBZ-aspartic acid-glutamic acid-valine-aspartic acid-fluoromethyl ketone (z-DEVD-fmk; 0.67 µg/ml). The CsA was purchased from NovartisSandoz (Arnhem, The Netherlands; provided in a 50-mg/ml intravenous infusion solution). z-DEVD-fmk was purchased from Calbiochem-Novabiochem (Nottingham, UK) and kept in DMSO stock solutions. For this report CsA and z-DEVD-fmk were neither tested at multiple doses nor in 2% FBS.
Statistical Analysis and Immunocytochemistry
All retinal explants were cultured up to PN28. The tissue was
fixed in 4% paraformaldehyde, infiltrated with 25% sucrose in
Sörensens phosphate buffer, cryosectioned (810 µm) and
stained using hematoxylin and eosin (H&E). These sections were viewed
and either accepted into or rejected from the explant population.
Accepted explants were assigned a neutral tag (consecutive numbers).
Exclusion criteria included a dead explant or presence of fibroblast
growth. Links between fibroblast growth and a particular treatment were
not analyzed and therefore cannot be excluded. To draw inferences about
the accepted population, 4 samples (explants) from each category
(number of explants per category, at least 13) were taken at random and
the number of rows in a vertical column of the outer nuclear layer
(ONL) counted. Two experienced observers, who were uninformed about
each others results, collected the data.
Variability between counts was negligible. For cultured explants ONL column counts was used as a measure, because we and others21 have observed that any distortion of the tissue tends to affect the thickness of the ONL more than the number of somata in a vertical column. The number of four explants was decided to be adequate, serving as a good approximation unless indicated otherwise by statistical analysis. Counts were from central regions of sections with flat ONL, because the explants flatten off or show higher degrees of rosettes at the periphery. For reasons explained later, data from PN2 and PN7 explants of the same category were pooled. The highest number of rows of nuclei in the ONL (for maximum effect) was noted, and comparisons were made using one-way analysis of variance (ANOVA) at the 5% significance level, followed by Fishers protected least-significant difference post hoc comparisons. It was not possible to section explants according to retinal horizontal or vertical planes. Therefore, it could not be determined whether counts were from superior or inferior parts of the central retina. The cells in the inner nuclear layer (INL) and ganglion cell layer were not analyzed.
The identity and state of differentiation of individual cell types in the ONL were further investigated by immunocytochemistry. Four antibodies were used: a polyclonal opsin antibody (AO, 1:15,000), a polyclonal arrestin antibody (1:30,000), a monoclonal green cone antibody (COS-1, 1:2,000), and a monoclonal blue cone antibody (OS-2, 1:2,000).12 22 Secondary antibodies conjugated with biotin that was reacted with avidin-horseradish peroxidase (avidin-HRP) and diaminobenzidine (DAB; Vector, Burlingame, CA) detected the bound antibodies. All histochemical and immunocytochemical reactions were examined and reproduced with either a photomicroscope (Axiophot: Zeiss, Oberkochen, Germany) or a microscope (BX60; Olympus, Lake Success, NY) equipped with Optronics image analysis hardware operated by image analysis software (Micro Image; Olympus) on a desktop computer (Presario; Compaq, Houston, TX).
| Results |
|---|
|
|
|---|
|
|
|
CNTF+BNTF
Tables 2
and 3
summarize the results obtained when the retina was subjected to
CNTF+BDNF during development in culture up to PN28. Administration of
50 ng/ml CNTF+BDNF to a 10% serum-containing medium maintained
6.5 ± 0.2 rows in the ONL of rd explants. A similar
treatment of these explants put in 2% serum-containing medium resulted
in 7.0 ± 0.4 rows of cells in the ONL. CNTF+BDNF (10 ng/ml) in
10% FBS medium showed 7.0 ± 0.4 rows of photoreceptor cells,
whereas after addition of 10 ng/ml of this survival factor in 2% FBS
medium 6.9 ± 0.1 rows were observed in the ONL of rd
explants. Supplement of 50 ng/ml CNTF+BDNF to +/+ explants cultivated
in high serum levels led to survival of 8.4 ± 0.1 rows of
photoreceptor nuclei, whereas the same treatment to control explants
cultured in low serum levels resulted in 8.4 ± 0.2 rows of cells
in the ONL. CNTF+BDNF (10 ng/ml) displayed an ONL thickness of 8.1 ± 0.4 and 8.3 ± 0.2 rows of photoreceptor nuclei in control
explants cultured in 10% and 2% FBS media, respectively.
Comparisons of CNTF, BNDF, and CNTF+BDNF
Figure 1
displays histologic images from the untreated rd control
(Fig. 1A) , followed by the rd retinal explant treated with
10 ng/ml CNTF (Fig. 1B)
, BDNF (Fig. 1C)
, or CNTF+BDNF (Fig. 1D)
, when
cultured in a 2% serum-containing medium. Companion +/+ explants are
depicted in Figures 1E
1F
1G
1H
. In both serum conditions, all the
CNTF treatments had a statistically significant rescue effect
(P < 0.001) in rd explants when compared
with vehicle treatment. On average, the number of rows in the
rd ONL was twofold in CNTF-treated explants compared with
vehicle treatment. ONL counts in CNTF-treated rd retinas
were not statistically different between high- and low-serum
conditions. There were no significant differences when 10 ng/ml or 50
ng/ml CNTF was applied. Compared with BDNF, CNTF had a significant
rescue effect in 10%, but not in 2%, FBS medium. Comparisons between
BDNF and vehicle treatments of rd explants showed a
statistically significant (P < 0.05; except 10 ng/ml
BDNF in both serum concentrations) rescue of photoreceptors by BDNF. No
statistically significant differences were found between high and low
concentrations of BDNF when tested in rd explants. High- and
low-serumcontaining media produced similar effects when BDNF was
tested. In rd explants, all cases of CNTF+BDNF treatment
resulted in a significant (P < 0.001) rescue effect in
comparison with vehicle treatment. On average, CNTF+BDNF produced three
times as many rows in the ONL of rd explants when compared
with vehicle treatment. Again, the low dose of the combination
treatment had already produced the maximum effect. CNTF+BDNF ONL cell
counts were twice those of BDNF and 1.5 times that of CNTF.
|
Figure 2 illustrates part of the statistical comparisons between treatments by showing the interaction bar plots (mean ± SEM) for the vehicle-treated +/+ and rd explants and the 10 ng/ml neurotrophic factor drug treatments of rd explants.
|
|
|
|
Apoptosis Inhibitors
Both CsA and z-DEVD-fmk failed to block rd
photoreceptor cell loss in 10% FBS medium. Other observations at the
light microscopy level included some photoreceptor nuclei dislocated to
the subretinal space. Photoreceptor cell bodies in areas with overlying
RPE showed outer segment disc material, whereas in areas without
attached RPE, only inner segments were observed.
| Discussion |
|---|
|
|
|---|
If these properties are taken into account and proper controls are used, this technique can be used to generate valid information regarding altered numbers of ONL cells in response to treatment. The organ culture method can be compared with culturing many different cell types simultaneously. Their nutritional requirements may vary from one cell to another. We therefore elected to add serum, containing proteins and polypeptides, carbohydrates, hormones, and vitamins that were unknown to the experimenter but often necessary for more demanding cell lines. When performance between the high- and low-serumcontaining media is compared, the evidence does not suggest major interference by unknown serum factors in our system. The observation that in 2% FBS medium slightly more photoreceptor cells survived than in 10% FBS medium is a sign that high serum levels should be avoided. This corresponds to data published by Gaur et al.24 Because all the ONL counts have been performed on retinas with RPE attached (this produced more stability) we cannot say whether the presence of RPE is necessary to produce a beneficial effect by the applied treatments.
Neurotrophic FactorMediated RPE Effects on Photoreceptor-Specific
Protein Expression
Some investigators have reported that CNTF on its own can
significantly block apoptosis.14
25
In our system CNTF has
maintained approximately 4.5 ONL rows, which, when left untreated,
would have decreased to 2.4 rows in the rd retina by PN28.
Thus, CNTF was able to rescue rd retinal photoreceptors on
its own, as published earlier.26
BDNF application, when
compared with CNTF, resulted in less delay of rd cell loss,
which is in agreement with findings by others.14
CNTF+BDNF, however, has shown to be the most potent photoreceptor
rescue, maintaining approximately seven ONL rows in the rd
retina. This is a synergistic effect from both individual proteins and
is generated when the tissue is continuously exposed to 10 ng/ml of the
combination therapy. In this case we have not visualized whether the
neurotrophic factor treatment affects either the rate of cell death or
mitosis. Alterations of either can lead to cell gain, but other studies
using either identical treatment or other neurotrophic factors have
reported arrest of disease and no increase in
mitosis.13
14
15
16
17
18
19
Currently, we are investigating the time
during which the first exposure to the combination treatment is
effective and whether subsequent intermittent applications can maintain
photoreceptor rescue up to PN28.
The present result is in accordance with data demonstrating that
simultaneous administration of CNTF and BDNF significantly inhibits
motor neuron loss in the Wobbler mouse in contrast to these agents
alone.19
It is also similar to the earlier finding that
FGF2, combined with NGF but not applied individually, saves
rd photoreceptors in culture.12
Synergistic
interactions between various neurotrophic factors are now a recurring
phenomenon and have been superior over the individual
agents.27
28
As yet, it remains unresolved how CNTF+BDNF
combination therapy, for which the ligand receptors are not expressed
by the photoreceptors themselves but are located on the neighboring
retinal RPE and Müller glia cells,29
30
31
32
33
transmit
their signal to the photoreceptor cell nuclei. The use of Trk B and
CNTFR-
antibodies may provide important clues about the mechanism.
In this study, we also observed that CNTF or CNTF+BDNF causes a reduction in opsin and arrestin immunoreactivity in photoreceptor cell bodies that overlay the RPE. This effect is stronger for opsin than for arrestin expression. Using rat dissociated rods CNTF also blocks rod differentiation, but this capability of CNTF diminishes with maturation of the cells.20 We agree with this concept; however, our interpretation is that this phenomenon is selective and incomplete. This issue is important, because it suggests that promoting rod survival by this type of drug therapy may compromise function at the same time. Using electroretinography, a similar phenomenon has been noted recently by Gargini et al.34 Loss of function is one of the first serious side effects to be considered when neurotrophic factors are used to rescue retinal cells. An explanation for the observed side effects by CNTF or CNTF+BDNF may be found in the kinds of interactions engaged by these neurotrophic factors and the RPEretinainterphororecaptor matrix (IPM) complex. The hypothesis is that these interactions promote rod photoreceptor cell survival but delay rod photoreceptor differentiation. Strong support comes from Layer et al.35 who, looking for effects of the RPE on histogenesis of the avian retina in vitro, have come to the conclusion that RPE extends cell proliferation, whereas differentiation is much delayed. They found that the effects of RPE on rod differentiation occur without the influence of neurotrophic factors. In our retinal organ culture, however, the strong delay in rod differentiation by the RPE occurs only under the influence of CNTF and BDNF. This indicates that in the mouse the action of these neurotrophic factors is direct or indirect through the RPE.
FGF2 is released by the RPE and likely also by Müller cells in response to CNTF36 and is able to directly stimulate photoreceptors.37 Therefore, FGF2 is a strong candidate to function as a messenger between the neurotrophic factors acting on the RPEretinaIPM complex on the one hand and the photoreceptors on the other hand. In contrast, it has also been discovered that FGF2 antibodies inhibit the differentiation of neural retina without an effect on apoptosis or proliferation.38 In a previous study in which we analyzed FGF2+NGF rescue of rd photoreceptor cells in organ culture, an RPE modulation of opsin immunoreactivity was not noticed. This suggests some functional differences between elevated FGF2 levels due to RPE secretion and those due to added recombinant bovine FGF2. In any case, to minimize any impact on rod function, a safety and efficacy evaluation of survival factors including retinal metabolic parameters should be conducted before these drugs are used in clinical trials.
No Effect of Apoptotic Pathway Inhibitors on rd Cell
Loss In Vitro
We have begun evaluating CsA as a potential drug for inhibiting
photoreceptor cell loss through apoptosis. CsA blocks release of
cytochrome c from mitochondria, which prevents activation of
caspase 9, acting upstream of caspase 3, the proximal caspase in the
apoptotic pathway.39
40
When rd retina was
exposed to 25 µg/ml CsA in 10% FBS medium, rescue from cell loss was
not observed. The dosage used in the current study was the same as the
one used to stop thyroid-induced apoptotic regression of the tadpole
tail.40
However, in another study using T cells, apoptosis
has been effectively blocked using a 1-µg/ml concentration of
CsA.41
Therefore, the dosage used in our experiment may
have been too high, inducing interference with the inhibition of
photoreceptor cell apoptosis. Söderpalm et al.42
have reported recently that z-VAD-fmk, a broad-spectrum caspase
blocker, effectively stops retinoic acid-induced photoreceptor cell
death in vitro. Caspase-3 is activated in transgenic rats with opsin
mutation S334ter, and photoreceptor loss through apoptosis can be
delayed by intraocular injection with z-DEVD-fmk.43
z-DEVD-fmk is a caspase-3selective inhibitor. We did not observe
z-DEVD-fmkinduced rescue of mouse rd cells in vitro. In a
preliminary study, Chong et al.44
have injected several
caspase inhibitors into the vitreous of the retinal degeneration slow
(rds) and rd mice. They found only an effect of
the caspase-3 inhibitor III (Ac-DEVD-CMK) in the rds mouse.
No significant effects have been found either from the other treatments
or in the rd mouse. This is similar to our experience, which
supports the conclusion by Chong et al.44
that the
protective effect by the caspase-3 inhibitors is ambiguous or better,
selective to specific mutations. Because little information is
currently available about retinal specificity, proper dosage, when to
begin therapy, and best delivery regimen for caspase inhibitors,
further studies are needed. In any case, the emerging picture from
these apoptosis blockers is relevant to the neurotrophic factor issue.
From the experimental drug treatments for inherited retinal
degeneration currently under investigation, CNTF, and BDNF rank as the
most potent and consistent broad-spectrum treatment when assayed in
vitro. This warrants taking the next step: an in vivo comparison of
this combination therapy against alternatives like
diltiazem.45
It is from these systematic in vitro
screenings followed by in vivo testing that true successful
pharmacologic therapies for retinal degeneration will emerge.
| Footnotes |
|---|
Submitted for publication January 4, 2000; revised March 31, July 21, and September 13, 2000; accepted September 28, 2000.
Commercial relationships policy: N.
Corresponding author: Theo van Veen, Wallenberg Retina Center, Department of Ophthalmology, Lund University Hospital, S-221 85 Lund, Sweden. theo.van_veen{at}oft.lu.se
| References |
|---|
|
|
|---|
-aminoadipic acid) Anat Embryol 196,67-79[Medline][Order article via Infotrieve]
This article has been cited by other articles:
![]() |
M. E. Pease, D. J. Zack, C. Berlinicke, K. Bloom, F. Cone, Y. Wang, R. L. Klein, W. W. Hauswirth, and H. A. Quigley Effect of CNTF on Retinal Ganglion Cell Survival in Experimental Glaucoma Invest. Ophthalmol. Vis. Sci., May 1, 2009; 50(5): 2194 - 2200. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Abe, R. Wakusawa, H. Seto, N. Asai, T. Saito, and K. Nishida Topical Doxycycline Can Induce Expression of BDNF in Transduced Retinal Pigment Epithelial Cells Transplanted into the Subretinal Space Invest. Ophthalmol. Vis. Sci., August 1, 2008; 49(8): 3631 - 3639. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. M. Paskowitz, K. M. Donohue-Rolfe, H. Yang, D. Yasumura, M. T. Matthes, K. Hosseini, C. M. Graybeal, G. Nune, M. A. Zarbin, M. M. LaVail, et al. Neurotrophic Factors Minimize the Retinal Toxicity of Verteporfin Photodynamic Therapy Invest. Ophthalmol. Vis. Sci., January 1, 2007; 48(1): 430 - 437. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Doonan, M. Donovan, and T. G. Cotter Activation of Multiple Pathways during Photoreceptor Apoptosis in the rd Mouse Invest. Ophthalmol. Vis. Sci., October 1, 2005; 46(10): 3530 - 3538. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Rohrer, F. R. Pinto, K. E. Hulse, H. R. Lohr, L. Zhang, and J. S. Almeida Multidestructive Pathways Triggered in Photoreceptor Cell Death of the RD Mouse as Determined through Gene Expression Profiling J. Biol. Chem., October 1, 2004; 279(40): 41903 - 41910. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Bush, B. Lei, W. Tao, D. Raz, C.-C. Chan, T. A. Cox, M. Santos-Muffley, and P. A. Sieving Encapsulated Cell-Based Intraocular Delivery of Ciliary Neurotrophic Factor in Normal Rabbit: Dose-Dependent Effects on ERG and Retinal Histology Invest. Ophthalmol. Vis. Sci., July 1, 2004; 45(7): 2420 - 2430. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Grimm, A. Wenzel, D. Stanescu, M. Samardzija, S. Hotop, M. Groszer, M. Naash, M. Gassmann, and C. Reme Constitutive Overexpression of Human Erythropoietin Protects the Mouse Retina against Induced But Not Inherited Retinal Degeneration J. Neurosci., June 23, 2004; 24(25): 5651 - 5658. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Seydewitz, A. Rothermel, S. Fuhrmann, A. Schneider, W. J. DeGrip, P. G. Layer, and H.-D. Hofmann Expression of CNTF Receptor-{alpha} in Chick Violet-Sensitive Cones with Unique Morphologic Properties Invest. Ophthalmol. Vis. Sci., February 1, 2004; 45(2): 655 - 661. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Lawrence, D. J. Keegan, E. M. Muir, P. J. Coffey, J. H. Rogers, M. J. Wilby, J. W. Fawcett, and R. D. Lund Transplantation of Schwann Cell Line Clones Secreting GDNF or BDNF into the Retinas of Dystrophic Royal College of Surgeons Rats Invest. Ophthalmol. Vis. Sci., January 1, 2004; 45(1): 267 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Keegan, P. Kenna, M. M. Humphries, P. Humphries, D. I. Flitcroft, P. J. Coffey, R. D. Lund, and J. M. Lawrence Transplantation of Syngeneic Schwann Cells to the Retina of the Rhodopsin Knockout (Rho-/-) Mouse Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3526 - 3532. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Doonan, M. Donovan, and T. G. Cotter Caspase-Independent Photoreceptor Apoptosis in Mouse Models of Retinal Degeneration J. Neurosci., July 2, 2003; 23(13): 5723 - 5731. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-W. M. Koh Ciliary Neurotrophic Factor Released by Corneal Endothelium Surviving Oxidative Stress Ex Vivo Invest. Ophthalmol. Vis. Sci., September 1, 2002; 43(9): 2887 - 2896. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |